<DOC>
	<DOCNO>NCT00732498</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Radiolabeled monoclonal antibody , yttrium Y 90 ibritumomab tiuxetan , find cancer cell carry cancer-killing substance without harm normal cell . Giving combination chemotherapy together rituximab yttrium Y 90 ibritumomab tiuxetan may kill cancer cell . PURPOSE : This phase II trial study give combination chemotherapy follow rituximab yttrium Y 90 ibritumomab tiuxetan see well work treat patient relapse stage II , stage III , stage IV follicular non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Rituximab , Yttrium Y 90 Ibritumomab Tiuxetan Patients W/Relapsed Stage II , III , IV Follicular NHL</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate 1-year progression-free survival patient relapsed stage II-IV follicular non-Hodgkin lymphoma treat ESHAP chemotherapy cytoreduction follow yttrium Y 90 ibritumomab tiuxetan radioimmunotherapy . - To evaluate median time progression patient . Secondary - To evaluate overall complete response rate patient treated regimen . OUTLINE : - ESHAP chemotherapy : Patients receive ESHAP chemotherapy comprise etoposide IV 1 hour , methylprednisolone IV , cisplatin IV day 1-4 , cytarabine IV 2 hour day 1 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . - Radioimmunotherapy : Between 4-6 week completion ESHAP chemotherapy , patient receive rituximab IV follow indium In 111 ibritumomab tiuxetan IV 10 minute day 1 . Patients &lt; 25 % bone marrow involvement expect biodistribution proceed treatment . Patients receive rituximab IV follow yttrium Y 90 ibritumomab tiuxetan IV 10 minute day 7 , 8 , 9 . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Diagnosis follicular nonHodgkin lymphoma ( NHL ) Bulky stage II , stage III , stage IV disease , Bulky disease define tumor measure 10.0 cm occupy ≥ onethird chest diameter In first , second , third , fourth relapse chemotherapy Unilateral bilateral bone marrow aspirate biopsy cytogenetics within past 42 day Tumor CD20 positive either flow cytometry immunoperoxidase stain paraffin section use antiCD20 antibody Bidimensionally measurable disease Patients nonmeasurable disease addition measurable disease must nonmeasurable disease assess within past 42 day No presence CNS lymphoma No chronic lymphocytic leukemia No HIV AIDSrelated lymphoma No presence pleural effusion Zubrod performance status 02 ANC ≥ 1,500/μL ( unless decrease count due marrow involvement NHL ) Platelet count &gt; 100,000/μL ( unless decrease count due marrow involvement NHL ) Serum creatinine ≤ 2.0 mg/dL Creatinine clearance ≤ 50 mL/min Serum bilirubin ≤ 2.0 mg/dL No renal insufficiency renal failure No known HIV positivity Not pregnant nursing No prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer 5year diseasefree status No impair bone marrow reserve , include follow : Hypocellular bone marrow ( cellularity ≤ 15 % ) Marked ( ≥ 10 % ) reduction bone marrow precursor one cell line ( granulocytic , megakaryocytic , erythroid ) ( beyond would expect patient 's age bone marrow cellularity ) History fail stem cell collection No serious , nonmalignant disease infection , opinion investigator and/or sponsor , would compromise protocol objective At least 3 week since prior therapy ( 6 week rituximab ) recover No prior myeloablative therapy autologous bone marrow transplantation peripheral blood stem cell rescue No prior radioimmunotherapy No prior external beam radiotherapy &gt; 25 % active bone marrow ( involved field regional ) More 4 week since prior major surgery , diagnostic surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
</DOC>